Evidence map›Paper›PMID 38590646›Full record

ReviewFrontiers in oncology2024

Research progress on the antitumor effects of harmine.

Yonghua Hu, Xiaoli Yu, Lei Yang, Gaimei Xue, Qinglin Wei, Zhijian Han, Hao Chen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Potential anticancer effects ofFrontiers in pharmacology · 2025
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yonghua HuKey Laboratory of the Digestive System Tumors of Gansu Province, Department of Tumor Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Xiaoli YuThe First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, China.
Lei YangThe First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, China.
Gaimei XueThe First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, China.
Qinglin WeiAffiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China.
Zhijian HanKey Laboratory of the Digestive System Tumors of Gansu Province, Department of Tumor Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Hao ChenKey Laboratory of the Digestive System Tumors of Gansu Province, Department of Tumor Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Gansu University of Traditional Chinese Medicine · CNLanzhou University · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harmine is a naturally occurring β-carboline alkaloid originally isolated from

Indexed as

antitumor effectderivativesharminemechanism of actionPeganum harmalaβ-carboline alkaloid

Identifiers

PMID38590646
PMCPMC10999596
OpenAlexW4393156741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.